[{"id":"6496b67a-0445-408d-84b5-b4ec4d9b149e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06846463","created_at":"2025-03-03T10:04:54.767Z","updated_at":"2025-03-03T10:04:54.767Z","phase":"Phase 2","brief_title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","source_id_and_acronym":"NCT06846463","lead_sponsor":"Virginia Commonwealth University","biomarkers":" BCL2 • NOTCH1 • MYD88 • CD79B • CD5","pipe":"","alterations":" ","tags":["BCL2 • NOTCH1 • MYD88 • CD79B • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/31/2029","primary_completion_date":" 07/31/2029","study_txt":" Completion: 07/31/2032","study_completion_date":" 07/31/2032","last_update_posted":"2025-02-26"},{"id":"3272fb35-7910-45fd-a4ab-4ef1f176f237","acronym":"BGB-3111-218","url":"https://clinicaltrials.gov/study/NCT05068440","created_at":"2021-10-05T20:00:21.125Z","updated_at":"2025-02-25T12:38:01.088Z","phase":"Phase 2","brief_title":"Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib","source_id_and_acronym":"NCT05068440 - BGB-3111-218","lead_sponsor":"BeiGene","biomarkers":" CD79B","pipe":" | ","alterations":" CD79B mutation • CD79B mutation","tags":["CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B mutation • CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 08/11/2021","start_date":" 08/11/2021","primary_txt":" Primary completion: 10/21/2025","primary_completion_date":" 10/21/2025","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2025-02-24"},{"id":"eb87323c-0942-4abb-b43f-af01b1dff7f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015880","created_at":"2023-12-26T19:17:43.252Z","updated_at":"2025-02-25T17:32:19.406Z","phase":"Phase 1","brief_title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT06015880","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD79B • CD4","pipe":" | ","alterations":" CD79B expression","tags":["IFNG • CD79B • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/20/2024","start_date":" 05/20/2024","primary_txt":" Primary completion: 06/29/2026","primary_completion_date":" 06/29/2026","study_txt":" Completion: 06/29/2026","study_completion_date":" 06/29/2026","last_update_posted":"2025-01-30"},{"id":"50186f31-5ca5-4488-bd84-bf563991c783","acronym":"","url":"https://clinicaltrials.gov/study/NCT04438005","created_at":"2021-01-18T21:21:51.408Z","updated_at":"2024-07-02T16:35:04.228Z","phase":"Phase 2","brief_title":"A Study of ICP-022 in Patients With R/R DLBCL","source_id_and_acronym":"NCT04438005","lead_sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","biomarkers":" MYD88 • CD79B","pipe":" | ","alterations":" MYD88 L265P","tags":["MYD88 • CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 L265P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inokai (orelabrutinib)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 05/07/2020","start_date":" 05/07/2020","primary_txt":" Primary completion: 11/05/2021","primary_completion_date":" 11/05/2021","study_txt":" Completion: 12/13/2021","study_completion_date":" 12/13/2021","last_update_posted":"2024-05-13"},{"id":"823e6ed4-d491-4855-84f3-188f083e1b0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06026319","created_at":"2023-09-07T16:09:32.477Z","updated_at":"2024-07-02T16:35:07.129Z","phase":"Phase 1","brief_title":"CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT06026319","lead_sponsor":"Marcela V. Maus, M.D.,Ph.D.","biomarkers":" CD79B","pipe":"","alterations":" ","tags":["CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/26/2023","start_date":" 10/26/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-04-29"},{"id":"0a498da3-5052-4cfe-b07c-4435fee18fe1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04668365","created_at":"2021-01-19T20:44:06.435Z","updated_at":"2024-07-02T16:35:47.692Z","phase":"Phase 2","brief_title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04668365","lead_sponsor":"Henan Cancer Hospital","biomarkers":" MYC • BCL2 • CD79B • CD79A","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["MYC • BCL2 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • cytarabine • cyclophosphamide • oxaliplatin • Brukinsa (zanubrutinib) • epirubicin • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/25/2020","start_date":" 12/25/2020","primary_txt":" Primary completion: 12/25/2023","primary_completion_date":" 12/25/2023","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2023-05-18"},{"id":"bcba688d-ccf2-45b4-927a-b48dc238e7e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05596097","created_at":"2022-10-27T15:58:27.582Z","updated_at":"2024-07-02T16:36:01.746Z","phase":"Phase 2","brief_title":"Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission","source_id_and_acronym":"NCT05596097","lead_sponsor":"LanZhou University","biomarkers":" TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["TP53 • MYC • BCL2 • MYD88 • BCL6 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/30/2022","start_date":" 10/30/2022","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2022-10-27"},{"id":"a15f3c21-a490-40cc-93c8-4d2c83593905","acronym":"","url":"https://clinicaltrials.gov/study/NCT05290337","created_at":"2022-03-22T12:52:47.199Z","updated_at":"2024-07-02T16:36:15.000Z","phase":"Phase 2","brief_title":"ZR-CHOP in DLBCL With Specific Gene Abnormality","source_id_and_acronym":"NCT05290337","lead_sponsor":"Fudan University","biomarkers":" TP53 • MYC • MYD88 • CD79B","pipe":" | ","alterations":" TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation","tags":["TP53 • MYC • MYD88 • CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 01/04/2022","start_date":" 01/04/2022","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2022-03-22"},{"id":"a86fead0-6d68-4e5e-8342-7224d15b5ca0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04994626","created_at":"2021-08-06T12:53:05.326Z","updated_at":"2024-07-02T16:36:26.846Z","phase":"Phase 2","brief_title":"Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies","source_id_and_acronym":"NCT04994626","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" CD20 • MYD88 • CD79B • CD79A","pipe":" | ","alterations":" CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation","tags":["CD20 • MYD88 • CD79B • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B mutation • CD79A mutation • CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2021-08-06"},{"id":"cd31500e-6fc2-462e-ae45-6974a2bb837f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04609241","created_at":"2021-01-19T20:32:05.435Z","updated_at":"2024-07-02T16:36:39.407Z","phase":"Phase 1","brief_title":"CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT04609241","lead_sponsor":"Zhejiang University","biomarkers":" CD79B • IL3RA","pipe":"","alterations":" ","tags":["CD79B • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79b CAR-T cell therapy"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 11/15/2020","start_date":" 11/15/2020","primary_txt":" Primary completion: 11/15/2023","primary_completion_date":" 11/15/2023","study_txt":" Completion: 11/15/2026","study_completion_date":" 11/15/2026","last_update_posted":"2020-10-30"},{"id":"307f73d9-02fe-4164-bff8-b7e3cc8feaa3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04429438","created_at":"2021-01-18T21:20:00.358Z","updated_at":"2024-07-02T16:36:44.235Z","phase":"Phase 1/2","brief_title":"Multi-CAR-T Cells Targeting B Cell Lymphomas","source_id_and_acronym":"NCT04429438","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD19 • CD79B • CD22 • CD70 • ANPEP","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD79B • CD22 • CD70 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e multi-CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-06-12"},{"id":"006e2786-ec9f-435c-b1a8-55c1b4f1678e","acronym":"PROTEOM","url":"https://clinicaltrials.gov/study/NCT04183569","created_at":"2021-01-18T20:23:47.835Z","updated_at":"2024-07-02T16:36:45.526Z","phase":"","brief_title":"Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT04183569 - PROTEOM","lead_sponsor":"University Hospital, Bordeaux","biomarkers":" BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1","pipe":" | ","alterations":" CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation","tags":["BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 32","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-04-29"},{"id":"152017c5-863c-4f69-9474-fce5cfa244fd","acronym":"ISRAEL","url":"https://clinicaltrials.gov/study/NCT03827603","created_at":"2021-01-18T18:54:13.311Z","updated_at":"2024-07-02T16:36:51.492Z","phase":"Phase 2","brief_title":"Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia","source_id_and_acronym":"NCT03827603 - ISRAEL","lead_sponsor":"Eugene Nikitin","biomarkers":" CD20 • CD79B • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD79B • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 02/21/2017","start_date":" 02/21/2017","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2020-01-10"},{"id":"bafce0ad-00a6-460c-ab9a-7c3dff70726f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02391116","created_at":"2021-01-18T11:24:02.780Z","updated_at":"2025-02-25T17:07:57.089Z","phase":"Phase 2","brief_title":"Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT02391116","lead_sponsor":"Bayer","biomarkers":" CD79B","pipe":"","alterations":" ","tags":["CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aliqopa (copanlisib)"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 05/08/2015","start_date":" 05/08/2015","primary_txt":" Primary completion: 07/05/2016","primary_completion_date":" 07/05/2016","study_txt":" Completion: 01/19/2018","study_completion_date":" 01/19/2018","last_update_posted":"2019-01-04"},{"id":"741f1d23-8352-458a-8b74-c72114763cb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01520922","created_at":"2021-01-18T06:23:52.354Z","updated_at":"2025-02-25T13:17:28.181Z","phase":"Phase 2","brief_title":"Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)","source_id_and_acronym":"NCT01520922","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD20 • IGH • CD79B • B2M • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • IGH • CD79B • B2M • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bendamustine • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2017-01-19"},{"id":"5c5e97c0-4f73-4509-98bd-2a742ec3a840","acronym":"","url":"https://clinicaltrials.gov/study/NCT01681563","created_at":"2021-01-18T07:17:09.017Z","updated_at":"2025-02-25T13:17:55.127Z","phase":"Phase 2","brief_title":"Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01681563","lead_sponsor":"Niguarda Hospital","biomarkers":" CD20 • CD79B • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD79B • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Arzerra (ofatumumab) • pentostatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2016-12-28"}]